Mid-Term Limb Salvage Following Plain Balloon Angioplasty for Severe Limb Ischaemia Due to Infra-Popliteal Disease: A Comparison of the Basil Trial (1999-2004) with a Contemporary Series (2009-2013)
Matthew Popplewell,Huw Davies,Mary Renton,Gareth Bate,Smitaa Patel,John Deeks,Andrew Bradbury
DOI: https://doi.org/10.1016/j.ejvs.2019.06.556
IF: 6.427
2019-01-01
European Journal of Vascular and Endovascular Surgery
Abstract:Introduction - Despite the only available level 1 evidence (from the UK NIHR HTA- funded BASIL-1 trial, B-1) showing superior outcomes from bypass, in recent years, there has been an increasing trend towards offering endovascular revascularisation (ER) to patients with severe limb ischaemia (SLI). This is frequently justified by asserting that the results of ER are likely to be significantly better now than when B-1 patients were treated. The aim of this study is to compare midterm clinical outcomes in patients undergoing IP ER in the B-1 (1999-2004) with those observed a decade later (2009-2013) in a contemporary series (CS) from an academic tertiary vascular unit. Methods - Patient data was obtained from prospectively gathered computerised B-1 (48 patients) and CS (73 patients) databases. Both groups had a minimum of 3 years of follow up. Patients undergoing IP revascularisation within the 12 months prior to intervention were excluded. The primary outcome measure was amputation free survival (AFS), with secondary outcomes of overall survival (OS), freedom from major lower limb amputation (above ankle), re-intervention, immediate technical success and length of hospital stay during index procedure and 12 months following intervention. Results - Patients in both cohorts were well matched at baseline for age, presence of diabetes mellitus, stroke, myocardial infarction and tissue loss. More patients in BASIL underwent concomitant superficial femoral (60% in BASIL, 37% CS, p=0.01) and above knee popliteal (60% vs. 34%, p=0.005) angioplasty. There was no use of drug eluting technology in either cohort. One patient in B-1 and 4 patients in the CS had a bail out bare metal stent placed in the superficial femoral artery. Immediate technical success improved from 73% in BASIL to 91% in the CS (p=0.01). Despite this, no improvements in AFS (HR=1.00, 95% CI: 0.66-1.54, p=1.0) (see figure), OS (HR=1.04, 95% CI: 0.66-1.63, p=0.9), re-intervention (HR=0.63, 95% CI: 0.31-1.26, p=0.23) or major (above ankle) amputation (HR=0.86, 95% CI: 0.38-1.96, p=0.7) were observed. Median length of hospital stay after index intervention and in the 12 months following intervention was significantly shorter in the CS (p=0.02 and p=0.006 respectively). Conclusion - Despite better technical success, there was no improvement in clinical outcomes between the two cohorts 1999-2004 and 2009-2013. Further randomised controlled trials, such as BEST-CLI (US) [2] and BASIL-2 (UK) [3] are clearly required to define evidence-based revascularisation strategies in patients with SLI. References1.Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925-34.2.Menard MT, Farber A. The BEST-CLI trial: a multidisciplinary effort to assess whether surgical or endovascular therapy is better for patients with critical limb ischemia. Semin Vasc Surg. 2014;27(1): 82-4.3.Popplewell MA, Davies H, Jarrett H, Bate G, Grant M, Patel S, et al. Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials. 2016;17: 11.